Silence Therapeutics Aktie

0,9700 USD +0,0200 USD +2,11 %

01.05.2025

NASO

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

WKNA1T9PD

ISINGB00B9GTXM62

SymbolSLNCF

Silence Therapeutics Aktien News

Sortieren:Datum Meistgelesen

09.12.24BusinesswireSilence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

26.11.24BusinesswireSilence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

18.11.24BusinesswireSilence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

14.11.24BusinesswireSilence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

27.08.24BusinesswireSilence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

15.08.24BusinesswireSilence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

27.06.24BusinesswireSilence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

24.06.24BusinesswireSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

20.06.24BusinesswireSilence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

30.05.24BusinesswireSilence Therapeutics to Present at Jefferies Global Healthcare Conference

16.05.24BusinesswireSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

30.04.24BusinesswireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

29.04.24BusinesswireSilence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

08.04.24BusinesswireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

13.03.24BusinesswireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

13.03.24BusinesswireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

28.02.24BusinesswireSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

23.02.24BusinesswireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

05.02.24BusinesswireSilence Therapeutics Announces Oversubscribed $120 Million Private Placement

31.01.24BusinesswireSilence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01.12.23BusinesswireSilence Therapeutics Strengthens Executive Leadership Team with Key Appointments

14.11.23BusinesswireSilence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

08.11.23BusinesswireSilence Therapeutics to Present at Jefferies London Healthcare Conference

01.11.23BusinesswireSilence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

06.09.23BusinesswireSilence Therapeutics to Participate in September Investor Conferences

16.08.23BusinesswireSilence Therapeutics Reports Second Quarter 2023 Results

31.05.23BusinesswireSilence Therapeutics to Present at the Jefferies Healthcare Conference

16.05.23BusinesswireSilence Therapeutics Reports First Quarter 2023 Results

04.05.23BusinesswireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

01.05.23BusinesswireSilence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

25.04.23BusinesswireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

04.04.23BusinesswireSilence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera

29.03.23BusinesswireSilence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

28.03.23BusinesswireSilence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

28.03.23BusinesswireSilence Therapeutics to Buyback siRNA Complement Assets

15.03.23BusinesswireSilence Therapeutics Reports Fourth Quarter and Full Year 2022 Results

02.03.23BusinesswireSilence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023

08.02.23BusinesswireSilence Therapeutics to Present at SVB Securities Global Biopharma Conference

06.02.23BusinesswireSilence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

12.01.23BusinesswireSilence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics News

Silence Therapeutics News: auf dieser Seite finden Sie alle Silence Therapeutics News und Nachrichten zur Silence Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Silence Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Silence Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.